Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are ...

"A bad day for science, and huge blow to our national security, this decision will have dangerous repercussion," one ...